Evaluation of the Dermatology Life Quality Index scoring modification, the DLQI‐R score, in two independent populations

Barbieri, John S.; Gelfand, Joel M.

doi:10.1111/bjd.17419

Cited by 19 publications

(28 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To address the issue, a new scoring, the DLQI‐Relevant (DLQI‐R) has been developed that adjusts the total DLQI score of patients for the number of NRRs . The DLQI‐R showed good validity and responsiveness to change in patients with psoriasis . However, a U.S. study did not recommend the use of the DLQI‐R and called for additional refinement and validation .…”

mentioning

confidence: 99%

“…The DLQI‐R showed good validity and responsiveness to change in patients with psoriasis . However, a U.S. study did not recommend the use of the DLQI‐R and called for additional refinement and validation . In addition to validity and responsiveness, other important measurement properties of the DLQI‐R scoring, such as discriminatory power, need to be confirmed to encourage its use in clinical practice and research.…”

mentioning

confidence: 99%

See 1 more Smart Citation

DLQI‐R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea

et al. 2019

View full text Add to dashboard Cite

Background The Dermatology Life Quality Index (DLQI) rates 'not relevant' responses (NRRs) as the item on the questionnaire having no impact on the patients' lives at all. The DLQI-Relevant (DLQI-R) is a recently developed scoring that adjusts the total score of the questionnaire for the number of NRRs indicated by a patient. Objectives To compare the discriminatory power of the original and DLQI-R scoring approaches in terms of absolute and relative informativity. Methods Cross-sectional data from 637 patients with morphea, pemphigus and psoriasis were used for the analyses. To assess absolute and relative informativity, Shannon's index and Shannon's evenness index were calculated for the 10 items on the questionnaire and for DLQI and DLQI-R total scores. Results Mean DLQI and DLQI-R scores of patients were 6Á13 vs. 6Á91. In the subset of patients with NRRs (n = 261, 41%), absolute informativity was higher with the DLQI-R scoring for all eight items with NRR options in all three conditions. The DLQI-R exhibited a better relative informativity in 8, 8 and 6 items in pemphigus, morphea and psoriasis, respectively. The DLQI-R led to an improvement in average item-level informativity in all DLQI score bands up to 20 points. Regarding total scores, the DLQI-R produced both a higher absolute and relative informativity in all three conditions. Conclusions In patients with morphea, pemphigus and psoriasis, DLQI-R scoring improves the discriminatory power of the questionnaire by benefiting from the additional information in NRRs. DLQI-R scoring may be useful both in clinical practice and research. A scoring chart has been developed to aid physicians with scoring.What's already known about this topic?• The original scoring of the Dermatology Life Quality Index (DLQI) rates 'not relevant' responses as the item of the questionnaire having no impact on the patients' lives at all.• DLQI-Relevant (DLQI-R) is a new scoring developed in 2018 that adjusts the total score of the questionnaire for the number of 'not relevant' responses indicated by patients.• The discriminatory power of the DLQI-R compared with the DLQI has not yet been investigated.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

DLQI‐R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The baseline characteristics, including gender, age, weight, body mass index (BMI), smoking history, drinking history, psychological obstacle, pathological type, family history of psoriasis, and lack of health knowledge, exhibited no significant differences between two groups (all P > 0.05) (Table ). Patients were classified as “mild” (n = 46), “moderate” (n = 35), and “severe” (n = 27) psoriasis according to the PASI …”

Section: Resultsmentioning

confidence: 99%

“…(n = 35), and "severe" (n = 27) psoriasis according to the PASI. 19 3.3 | The KRT16 protein and VEGF are highly expressed in the lesion tissues HE staining result showed that in psoriatic patients, keratosis was seen in lesions, granular layer decreased or disappeared, dermal papilla vasodilation was tortuous, inflammatory cell infiltration in dermis and subcutaneous tissue was obvious; while non-lesion tissues and normal skin tissues showed flatter epidermis, and the infiltration of inflammatory cells in non-lesion tissues was less (Figure 2A). The positive staining of KRT16 was expressed in the intracytoplasm.…”

Section: Baseline Characteristics Between Psoriatic Patients and Hementioning

confidence: 99%

Silencing KRT16 inhibits keratinocyte proliferation and VEGF secretion in psoriasis via inhibition of ERK signaling pathway

Chen

Fan

Wang

et al. 2019

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

Psoriasis is a multisystem disease affecting about 2% of the population, while keratin16 (KRT16) has been reported to participate in psoriasis. However, the specific mechanism of KRT16 in psoriasis was inadequately investigated. The objective of the study was to elucidate the mechanism by which siRNA‐mediated silencing of KRT16 affects keratinocyte proliferation and vascular endothelial growth factor (VEGF) secretion in psoriasis through the extracellular signal‐related kinase (ERK) signaling pathway. Psoriasis‐related core gene KRT16 was screened out. Then, the expression of KRT16, VEGF, and ERK signaling pathway‐related genes was detected in psoriatic patients. To further investigate the mechanism of KRT16, keratinocytes in psoriatic patients were treated with KRT16 siRNA or/and ERK inhibitor (PD98059) to detect the changes in related gene expression and cell survival. KRT16 was involved in psoriasis development. The expression levels of KRT16, p‐ERK1/2, and VEGF in lesion tissues are significantly elevated. Keratinocytes treated with KRT16‐siRNA and KRT16‐siRNA + PD98059 exhibited reduced KRT16, p‐ERK1/2, and VEGF expression. The cell survival rate in cells treated with KRT16‐siRNA, PD98059, and KRT16‐siRNA + PD98059 reduced significantly. These findings indicate that silencing KRT16 inhibits keratinocyte proliferation and VEGF secretion in psoriasis via inhibition of ERK signaling pathway, which provides a basic theory in the treatment of psoriasis.

show abstract

“…Construct validity of the DLQI-R scoring with PASI, EQ-5D-3L and EQ VAS was indicated by two independent studies in Hungary and the United States. 11,13 Switching to DLQI-R would be a way to keep on using the DLQI-a widely known and accepted outcome measure-while fixing the apparent bias of NRRs. Nevertheless, undertaking a series of methodological research to confirm the favourable psychometric properties of the DLQI-R is needed.…”

Section: Dear Editormentioning

confidence: 99%

Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines

Rencz

Brodszky

Gulàcsi

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Evaluation of the Dermatology Life Quality Index scoring modification, the DLQI‐R score, in two independent populations

Cited by 19 publications

References 6 publications

DLQI‐R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea

DLQI‐R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea

Silencing KRT16 inhibits keratinocyte proliferation and VEGF secretion in psoriasis via inhibition of ERK signaling pathway

Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines

Contact Info

Product

Resources

About